Elinzanetant: Emerging Therapy for Menopausal Hot Flashes

January 2026

Rx elinzanetant (Lynkuet) is now approved and adds a new nonhormonal option to the menopausal hot flash management toolbox.

Elinzanetant blocks neurokinin 1 (NK1) and neurokinin 3 (NK3) receptors...to reduce substance P and neurokinin B, neurotransmitters that regulate sleep and body temperature.

It’s similar to fezolinetant (Veozah)...an NK3 receptor blocker.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

Cutting-edge advice about new medications and how they fit into practice
Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Obesity & Weight Loss Address New GLP-1 Agonist Side Effect Concerns
Practice Point Out Caveats With Direct-to-Consumer Meds
Menopause Elinzanetant: Emerging Therapy for Menopausal Hot Flashes
Education and Training Weave AI Into Your Plan for Precepting Learners
Asthma Clear the Air on Asthma Treatment for Kids
Pediatrics Identify Changes to “KIDs List” Meds to Keep Children Safe
Hair Loss Get to the Root of Male Pattern Baldness Treatments
NatMed Spotlight Put Claims About Methylene Blue in Perspective

Elinzanetant: Emerging Therapy for Menopausal Hot Flashes

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Table of Contents